

Coverage of any drug intervention discussed in the plans prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and to applicable state and/or federal laws.

- Commercial (Small & Large Group) ASO Exchange/ACA
 Medicare Advantage (MAPD)
-

New-to-Market Medical Pharmacy Products Currently Under Clinical Review **MB2210**

Covered Service: Yes

Prior Authorization Required: N/A

Additional Information: None

Medicare Policy: Prior authorization is not required for Medicare Cost products (Dean Care Gold) and Medicare Supplement (Select) when this drug is provided by participating providers. Prior authorization is required if a member has Medicare primary and the plan secondary coverage. This policy is not applicable to our Medicare Replacement products.

Wisconsin Medicaid Policy Coverage of prescription drug benefits is administered by the Wisconsin Medicaid program. Coverage of medical drug benefits is administered by the Wisconsin Medicaid fee-for-service program. Medical drugs not paid on a fee-for-service basis by the Wisconsin Medicaid program are covered by the plan with no PA required.

Coverage of any drug intervention discussed in the plans prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and to applicable state and/or federal laws.

Updated 07/17/2024

Brand name	Generic name	J code	National Drug Codes (NDCs)	Date of FDA approval
Ahzantive	aflibercept-mrbb	J3590	not assigned	June 28, 2024
Amtagvi	lifileucel	J9999	73776-001-11 73776-001-12	February 16, 2024
Anktiva	nogapendekin alfa inbakicept-pmln	J9999	81481-0803-01	April 22, 2024
Beqvez	fidanacogene elaparvovec-dzkt	J3590	Multiple	April 26, 2024
Hepzato	Melphalan	J9999	75833-800-01	August 13, 2023
Hercessi	trastuzumab-strf	J9999	69448-0015-05	April 25, 2024
Imdelltra	tarlatamab-dlle	J9999	55513-0059-01 55513-0077-01	May 16, 2024
Kisunla	donanemab-azbt	J3590	00002-9401-01	July 2, 2024
Lenmeldy	atidarsagene autotemcel	J3590	83222-0200-01	March 18, 2024
Nypozi	filgrastim-txid	J3590	multiple	June 28, 2024
Opuviz	aflibercept-yszy	J3590	64406-0028-01 64406-0028-03	May 20, 2024
Piasky	crovalimab-akkz	J3590	50242-0115-01	June 20, 2024
Pyzchiva	ustekinumab-ttwe	J3590	multiple	June 28, 2024
Rytelo	imetelstat	J9999	82959-0112-01 82959-0111-01	June 6, 2024
Tevimbra	tislelizumab	J9999	72579-121-01	March 13, 2024
Winrevair	sotatercept-csrk	J3590	Multiple	March 26, 2024
Yesafili	aflibercept-jbvf	J3590	83257-0013-11	May 20, 2024
Yimmugo	Immune globulin IV, human – dira	J1599	Multiple	June 13, 2024

Note: Drugs recently removed from this list have been addressed under new drug management policies.

This list is provided for our provider network's convenience and information. While this list is intended to be comprehensive, the U.S. Food and Drug Administration (FDA) approval process and its timing is outside of the Plan's control. The Plan reserves the right to adjust claims for any new-to-market medical pharmacy products as discussed in the ['New-to-Market Medical Pharmacy Products'](#) coverage policy.

	Committee/Source	Date(s)
Document Created:	Medical Policy Committee/Health Services Division/Pharmacy Services	July 20, 2022
Revised:	Medical Policy Committee/Health Services Division/Pharmacy Services	September 21, 2022
	Medical Policy Committee/Health Services Division/Pharmacy Services	February 15, 2023

Coverage of any drug intervention discussed in the plans prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and to applicable state and/or federal laws.

Committee/Source	Date(s)
Medical Policy Committee/Health Services Division/Pharmacy Services	April 19, 2023
Medical Policy Committee/Health Services Division/Pharmacy Services	May 17, 2023
Medical Policy Committee/Health Services Division/Pharmacy Services	June 21, 2023
Medical Policy Committee/Health Services Division/Pharmacy Services	July 19, 2023
Medical Policy Committee/Health Services Division/Pharmacy Services	August 16, 2023
Medical Policy Committee/Health Services Division/Pharmacy Services	September 20, 2023
Medical Policy Committee/Health Services Division/Pharmacy Services	October 18, 2023
Medical Policy Committee/Health Services Division/Pharmacy Services	November 15, 2023
Medical Policy Committee/Health Services Division/Pharmacy Services	December 20, 2023
Medical Policy Committee/Health Services Division/Pharmacy Services	February 21, 2024
Medical Policy Committee/Health Services Division/Pharmacy Services	March 20, 2024,
Medical Policy Committee/Health Services Division/Pharmacy Services	April 17, 2024;
Medical Policy Committee/Health Services Division/Pharmacy Services	May 15, 2024;
Medical Policy Committee/Health Services Division/Pharmacy Services	June 20, 2024; July 17, 2024
Reviewed: Medical Policy Committee/Health Services Division/Pharmacy Services	September 21, 2022
Medical Policy Committee/Health Services Division/Pharmacy Services	February 15, 2023
Medical Policy Committee/Health Services Division/Pharmacy Services	April 19, 2023
Medical Policy Committee/Health Services Division/Pharmacy Services	May 17, 2023
Medical Policy Committee/Health Services Division/Pharmacy Services	June 21, 2023
Medical Policy Committee/Health Services Division/Pharmacy Services	July 19, 2023
Medical Policy Committee/Health Services Division/Pharmacy Services	August 16, 2023

Coverage of any drug intervention discussed in the plans prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and to applicable state and/or federal laws.

Committee/Source	Date(s)
Medical Policy Committee/Health Services Division/Pharmacy Services	September 20, 2023
Medical Policy Committee/Health Services Division/Pharmacy Services	October 18, 2023
Medical Policy Committee/Health Services Division/Pharmacy Services	November 15, 2023
Medical Policy Committee/Health Services Division/Pharmacy Services	December 20, 2023
Medical Policy Committee/Health Services Division/Pharmacy Services	February 21, 2024
Medical Policy Committee/Health Services Division/Pharmacy Services	March 20, 2024
Medical Policy Committee/Health Services Division/Pharmacy Services	April 17, 2024;
Medical Policy Committee/Health Services Division/Pharmacy Services	May 15, 2024;
	June 20, 2024; July 17, 2024

Effective: 07/17/2024
Published: 08/01/2024